KR20210149087A - 안과 질환을 치료하는 방법 - Google Patents

안과 질환을 치료하는 방법 Download PDF

Info

Publication number
KR20210149087A
KR20210149087A KR1020217034481A KR20217034481A KR20210149087A KR 20210149087 A KR20210149087 A KR 20210149087A KR 1020217034481 A KR1020217034481 A KR 1020217034481A KR 20217034481 A KR20217034481 A KR 20217034481A KR 20210149087 A KR20210149087 A KR 20210149087A
Authority
KR
South Korea
Prior art keywords
diabetic retinopathy
amd
age
ophthalmic disease
macular degeneration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217034481A
Other languages
English (en)
Korean (ko)
Inventor
쇼에이-셍 리
밍-자이 수
룽-제이알 린
차오-민 수
Original Assignee
지 위안 탕 바이오테크놀로지 코., 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 지 위안 탕 바이오테크놀로지 코., 엘티디. filed Critical 지 위안 탕 바이오테크놀로지 코., 엘티디.
Publication of KR20210149087A publication Critical patent/KR20210149087A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020217034481A 2019-04-03 2020-04-01 안과 질환을 치료하는 방법 Pending KR20210149087A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962828616P 2019-04-03 2019-04-03
US62/828,616 2019-04-03
US201962899279P 2019-09-12 2019-09-12
US62/899,279 2019-09-12
PCT/CN2020/082765 WO2020200241A1 (en) 2019-04-03 2020-04-01 Method for treating ocular diseases

Publications (1)

Publication Number Publication Date
KR20210149087A true KR20210149087A (ko) 2021-12-08

Family

ID=72662774

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217034481A Pending KR20210149087A (ko) 2019-04-03 2020-04-01 안과 질환을 치료하는 방법

Country Status (8)

Country Link
US (1) US11033603B2 (https=)
EP (1) EP3946414B1 (https=)
JP (1) JP7461663B2 (https=)
KR (1) KR20210149087A (https=)
CN (1) CN113795268B (https=)
SG (1) SG11202110659SA (https=)
TW (1) TWI818168B (https=)
WO (1) WO2020200241A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI788083B (zh) * 2021-11-03 2022-12-21 葡萄王生技股份有限公司 蟬花菌絲體活性物質用於治療黃斑部病變之用途
CN120936366A (zh) * 2023-03-20 2025-11-11 资元堂生物科技股份有限公司 一种白殭菌素用于制备抑制血管新生药物的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0327316A (ja) * 1989-06-23 1991-02-05 Kitasato Inst:The 高脂血症治療剤
KR20080031474A (ko) * 2005-07-27 2008-04-08 유니버시티 오브 플로리다 리서치 파운데이션, 아이엔씨. 안구 질환의 치료를 위한 열충격의 사용
CN101669939A (zh) * 2009-09-22 2010-03-17 中山大学 恩镰孢菌素类化合物在制备抗耐药结核菌药物中的应用
US20140275091A1 (en) * 2013-03-15 2014-09-18 Coyote Pharmaceuticals, Inc. Ocular formulations comprising geranylgeranylacetone derivatives for intraocular delivery
US20140371158A1 (en) * 2013-06-14 2014-12-18 Georgia Regents University Beauvericin compositions and methods thereof for inhibiting the hsp90 chaperone pathway
CN109200066A (zh) * 2017-07-07 2019-01-15 葡萄王生技股份有限公司 蝉花活性物质及其用于预防、延缓或治疗白内障的用途

Also Published As

Publication number Publication date
EP3946414A4 (en) 2022-12-07
US20200316165A1 (en) 2020-10-08
JP7461663B2 (ja) 2024-04-04
JP2022528566A (ja) 2022-06-14
CN113795268B (zh) 2025-04-08
WO2020200241A1 (en) 2020-10-08
TW202102252A (zh) 2021-01-16
EP3946414A1 (en) 2022-02-09
EP3946414B1 (en) 2025-12-03
CA3132137A1 (en) 2020-10-08
EP3946414C0 (en) 2025-12-03
CN113795268A (zh) 2021-12-14
US11033603B2 (en) 2021-06-15
TWI818168B (zh) 2023-10-11
SG11202110659SA (en) 2021-10-28

Similar Documents

Publication Publication Date Title
Audren et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: phase 2 trial comparing 4 mg vs 2 mg
Massin et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial
US8097640B2 (en) Prophylactic or therapeutic agent for diabetic maculopathy
KR101629670B1 (ko) 질환을 치료하기 위한 오메가 지방산의 용도
TW201316984A (zh) 治療乾眼病的組合物
KR20070094600A (ko) 안질환 치료제
Suto et al. A novel dual agonist of EP3 and FP receptors for OAG and OHT: safety, pharmacokinetics, and pharmacodynamics of ONO-9054 in healthy volunteers
El-Nimri et al. Comparison of the effects of latanoprostene bunod and timolol on retinal blood vessel density: a randomized clinical trial
US11033603B2 (en) Method for treating ocular diseases
WO2022221315A1 (en) Methods of treating retinal vasculopathies
Prokosch et al. Emerging syphilitic optic neuropathy: critical review and recommendations
Montgomery et al. Mechanisms underlying early-stage changes in visual performance and retina function after experimental induction of sustained dyslipidemia
CA3132137C (en) Method for treating ocular diseases
JP4578593B2 (ja) 糖尿病性網膜症治療のためのスロデキサイドを含有する医薬
Jovanović et al. Intravitreal bevacizumab injection alone or combined with macular photocoagulation compared to macular photocoagulation as primary treatment of diabetic macular edema
Mehra et al. Occurrence of cystoid macular edema after uneventful phacoemulsification in diabetic patients without retinopathy: a hospital-based comparative study
EP4364722A1 (en) Pharmaceutical composition for preventing or treating diabetic eye disease comprising sglt-2 inhibitor
Schilling et al. An elusive case of cystoid macular edema
Biricik et al. A comparison of the effects of propofol and thiopental on intraocular pressure in dogs
Garrigue et al. A comparative study of latanoprost-cationic emulsion (Catioprost) and latanoprost aqueous solution (Xalatan) in preclinical efficacy and safety models
Farag et al. Study of Structural Changes in Diabetic Macular Edema by Spectral Domain Optical Coherent Tomography after Intravitreal Injection of Triamcinolone Acetonide
Xie et al. O antagonista das prostaglandinas alivia a ruptura da barreira sanguínea retiniana induzida pela cirurgia intraocular do segmento anterior em um modelo em ratos

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000